287 related articles for article (PubMed ID: 10848822)
1. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
Haj MA; Robbie LA; Croll A; Adey GD; Bennett B
Intensive Care Med; 1998 Mar; 24(3):258-61. PubMed ID: 9565810
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
5. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
[TBL] [Abstract][Full Text] [Related]
6. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
7. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
11. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors.
Mukherjee M; Sembhi K; Kakkar VV
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):491-6. PubMed ID: 8840003
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
13. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
15. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T
Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
17. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]